527 related articles for article (PubMed ID: 28763468)
1. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
[TBL] [Abstract][Full Text] [Related]
2. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
[TBL] [Abstract][Full Text] [Related]
3. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
5. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
6. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
7. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
[TBL] [Abstract][Full Text] [Related]
8. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
Panopoulos ST; Bournia VK; Trakada G; Giavri I; Kostopoulos C; Sfikakis PP
Lung; 2013 Oct; 191(5):483-9. PubMed ID: 23925736
[TBL] [Abstract][Full Text] [Related]
10. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis.
Foeldvari I; Klotsche J; Hinrichs B; Helmus N; Kasapcopur O; Adrovic A; Sztajnbok F; Terreri MT; Anton J; Smith V; Katsicas M; Kostik M; Vasquez-Canizares N; Avcin T; Feldman B; Janarthanan M; Santos MJ; Sawhney S; Schonenberg-Meinema D; Sifuentes-Giraldo WA; Alexeeva E; Appenzeller S; Battagliotti C; Berntson L; Bica B; Costa-Reis P; Eleftheriou D; Kallinich T; Lehman T; Marrani E; Minden K; Nielsen S; Nuruzzaman F; Patwardhan A; Khubchandani R; Stanevicha V; Uziel Y; Torok KS
Arthritis Care Res (Hoboken); 2022 Mar; 74(3):364-370. PubMed ID: 33141441
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
[TBL] [Abstract][Full Text] [Related]
12. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
[TBL] [Abstract][Full Text] [Related]
15. Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.
Ciaffi J; van Leeuwen NM; Liem SIE; Ninaber MK; Huizinga TWJ; de Vries-Bouwstra JK
Clin Rheumatol; 2020 May; 39(5):1543-1549. PubMed ID: 31980971
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.
Caron M; Hoa S; Hudson M; Schwartzman K; Steele R
Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769294
[TBL] [Abstract][Full Text] [Related]
18. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
Yamakawa H; Takemura T; Iwasawa T; Yamanaka Y; Ikeda S; Sekine A; Kitamura H; Baba T; Iso S; Okudela K; Kuwano K; Ogura T
BMC Pulm Med; 2018 Jan; 18(1):25. PubMed ID: 29382307
[TBL] [Abstract][Full Text] [Related]
19. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
20. Predictors of progression in systemic sclerosis patients with interstitial lung disease.
Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
